文献速递主动脉疾病内脏/肾动脉与血管畸形

GORE EXCLUDER胸腹分支内假体(TAMBE)治疗近肾及IV型胸腹主动脉瘤的早期可行性研究:技术要点与30天结局

Technical aspects and 30-day outcomes of the prospective early feasibility study of the GORE EXCLUDER Thoracoabdominal Branched Endoprosthesis (TAMBE) to treat pararenal and extent IV thoracoabdominal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2019-01-03

这项前瞻性多中心早期可行性研究纳入13例近肾或IV型胸腹主动脉瘤患者,评估TAMBE内置假体的技术要点与30天安全性。技术成功12例(92%),无死亡、破裂、开放转换、透析或脊髓损伤;4例(31%)发生主要不良事件,均因术中失血>1000 mL。30天CTA显示靶血管通畅且无I型或III型内漏。

要点

  • TAMBE在近肾/IV型胸腹主动脉瘤中技术成功率高(92%),无死亡和脊髓损伤。
  • 30天主要不良事件发生率为31%,全部由术中失血>1000 mL导致。
  • 30天CTA显示靶血管通畅,无I型或III型内漏。

核心结论

  • 本研究证实TAMBE治疗近肾及IV型胸腹主动脉瘤的早期可行性,高技术成功率、无死亡和低并发症率支持扩大人群继续临床研究。

研究设计与样本

  • 前瞻性、多中心早期可行性研究,2014至2016年在美国5个中心及美国外1个中心纳入13例近肾或IV型胸腹主动脉瘤患者。
  • TAMBE包含四个分支端口,肾动脉端口可逆行或顺行配置,肾动脉和肠系膜动脉使用GORE VIABAHN球囊扩张式覆膜支架。
  • 主要终点为30天手术安全性,定义为无主要不良事件(任何原因死亡、心肌梗死、卒中、截瘫、肠缺血、呼吸衰竭、严重急性肾损伤(eGFR下降>50%)、透析及术中失血>1000 mL)。

主要发现

  • 共11例男性和2例女性,平均年龄69±8岁,平均动脉瘤直径61±13 mm。
  • 共重建52条肾动脉和肠系膜动脉(每例4条血管),技术成功12例(92%)。
  • 1例因夹层导致右肾动脉意外闭塞。
  • 无死亡、动脉瘤破裂、开放转换、透析或脊髓损伤,平均住院时间5±3天。
  • 30天时4例(31%)发生主要不良事件,均因术中失血>1000 mL;1例远端肾分支I型内漏经追加肾支架成功治疗。

临床怎么用

  • TAMBE可用于近肾及IV型胸腹主动脉瘤的血管腔内治疗,早期结果显示技术可行且安全性可接受。
  • 术中需关注失血量,失血>1000 mL是30天主要不良事件的主要原因。
  • 术后30天CTA应评估靶血管通畅性及内漏情况。

局限性

  • 样本量小(13例),随访仅30天,为早期可行性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study reports the technical aspects and 30-day outcomes of the prospective, multicenter early feasibility study designed to evaluate the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE; W. L. Gore & Associates, Flagstaff, Ariz). METHODS: Thirteen patients with pararenal or extent IV thoracoabdominal aortic aneurysms were prospectively enrolled at five U.S sites and one non-U.S. site from 2014 to 2016. The TAMBE included four portals with either retrograde or antegrade renal portal configuration and used GORE VIABAHN Balloon-Expandable Endoprosthesis (W. L. Gore & Associates) for stenting of the renal and mesenteric arteries. The primary end point was procedural safety at 30 days, defined by absence of major adverse events, including any-cause mortality, myocardial infarction, stroke, paraplegia, bowel ischemia, respiratory failure, severe acute kidney injury (>50% decline in estimated glomerular filtration rate), dialysis, and procedural blood loss >1000 mL. RESULTS: There were 11 male and two female patients with a mean age of 69 ± 8 years. Mean aneurysm diameter was 61 ± 13 mm. A total of 52 renal and mesenteric arteries were incorporated (4 vessels/patient). Technical success was achieved in 12 patients (92%). One patient had inadvertent occlusion of a right renal artery due to dissection. There was no mortality, aneurysm rupture, conversion to open repair, dialysis, or spinal cord injury. Mean length of hospital stay was 5 ± 3 days. At 30 days, four patients (31%) had major adverse events, all due to procedural blood loss >1000 mL. One patient had a type I endoleak at the distal renal branch, which was successfully treated by placement of an additional renal stent before dismissal. Computed tomography angiography at 30 days showed patent target vessels and no type I or type III endoleak. CONCLUSIONS: This study confirms the early feasibility of the TAMBE for treatment of pararenal and extent IV thoracoabdominal aortic aneurysms. The high technical success, no mortality, and low morbidity rate support continuation of clinical investigation in a larger population of patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Oderich GS, Farber MA, Silveira PG, et al. Technical aspects and 30-day outcomes of the prospective early feasibility study of the GORE EXCLUDER Thoracoabdominal Branched Endoprosthesis (TAMBE) to treat pararenal and extent IV thoracoabdominal aortic aneurysms. J Vasc Surg. 2019. PMID: 30612825. doi:10.1016/j.jvs.2018.10.103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。